Dongwu Securities released a research report on April 25 stating that it gave Puri Ophthalmology (301239.SZ) a purchase rating. The main reasons for the rating include: 1) Cataract achieved rapid growth in 2023, and gross margins of various businesses increased simultaneously; 2) the non-profit margin of all businesses increased significantly in 2023, and all expense ratios declined; 3) 2024Q1 revenue increased slightly and profits declined. It is expected that the reason is that the cataract business continues to grow and the refractive optometry business is under pressure. (Mainichi Keizai Shimbun)